Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin...
Diabetes MellitusType 2This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of patients with Type 2 diabetes mellitus (T2DM) already treated on maximum dose metformin.
A Study of LY2599506 in Patients With Type 2 Diabetes
Diabetes MellitusType 2The purpose of this study is to help answer the following questions: To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks. To evaluate the safety of LY2599506 in participants with diabetes. To determine if LY2599506 has the ability to control blood sugar in participants with diabetes. To determine how much LY2599506 should be given to participants. To determine if LY2599506 has an effect on a participant's weight. The study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8-week treatment period, and a 4-week follow-up period.
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi...
Type 2 Diabetes MellitusDiabetic Nephropathy1 moreThe purpose of this study is to evaluate the effect of FG-3019 on diabetic kidney disease or diabetic nephropathy.
Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)
Diabetes Mellitus Type 2A study to evaluate the effectiveness and tolerability of MK0533 and pioglitazone in patients with type 2 diabetes mellitus.
MK0767 in Type 2 Diabetes (0767-012)
Type 2 Diabetes MellitusThis is a clinical trial in patients with Type 2 Diabetes to test the safety of MK0767. This study will also see how effective MK0767 is in lowering markers of glucose metabolism and improving the lipid profile and non-HDL cholesterol when compared with placebo and pioglitazone.
Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM...
Type 2 DiabetesDiObex Inc. is developing an experimental drug (DIO-902) that is made up of part of the ketoconazole molecule for the treatment of elevated blood glucose associated with type 2 diabetes mellitus. Ketoconazole (Nizoral®) is a drug available by prescription for the treatment of fungal infections however DIO-902 is an investigational drug. DIO-902 may lower blood glucose by lowering levels of a naturally occurring hormone called cortisol. Elevated cortisol may contribute to the development of type 2 diabetes.
Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type...
Type 2 Diabetes MellitusHypertensionThe study will assess the efficacy and tolerability of MK0736 in patients with Type 2 Diabetes Mellitus and Hypertension who are on ongoing therapy with Angiotensin-Converting Enzyme or Angiotensin Receptor Blocker. After a 3 to 5 week pre-randomization phase, patients will be randomized to either MK0736 (3 doses), placebo, or hydrochlorothiazide (HCTZ). The study will also include a 3 week, posttreatment follow-up period.
A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)...
Type 2 Diabetes MellitusThis study assessed the safety and efficacy of MK-3577. The primary efficacy hypothesis was that, after 4 weeks of treatment, either the morning (AM) administration or the evening (PM) administration of MK-3577 provides superior reduction of 24-hour weighted mean glucose (WMG) levels compared to placebo (PLA). The primary safety hypothesis was that MK-3577 is well tolerated compared to placebo.
Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
Diabetes MellitusThe purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in treating subjects with type 2 diabetes mellitus.
Thiazolidinedione Intervention With Vitamin D Evaluation
Diabetes MellitusType 2This study will answer two separate questions. The first question is to test the cardiovascular effects of long-term treatment with rosiglitazone or pioglitazone when used as part of standard of care compared to similar standard of care without rosiglitazone or pioglitazone in patients with type 2 diabetes who have a history of or are at risk for cardiovascular disease. The second question will compare the effects of long-term supplementation of vitamin D on death and cancer